At the time of writing, Xilio Therapeutics Inc [XLO] stock is trading at $0.75, down -0.83%. An important factor to consider is whether the stock is rising or falling in short-term value. The XLO shares have gain 13.62% over the last week, with a monthly amount drifted -5.27%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Xilio Therapeutics Inc [NASDAQ: XLO] stock has seen the most recent analyst activity on December 21, 2022, when Chardan Capital Markets initiated its Buy rating and assigned the stock a price target of $7. Previously, H.C. Wainwright started tracking the stock with Buy rating on January 10, 2022, and set its price target to $36. On November 16, 2021, Raymond James initiated with a Outperform rating and assigned a price target of $31 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $32 on November 16, 2021. Guggenheim initiated its recommendation with a Buy and recommended $40 as its price target on November 16, 2021.
For the past year, the stock price of Xilio Therapeutics Inc fluctuated between $0.62 and $1.70. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Xilio Therapeutics Inc [NASDAQ: XLO] shares were valued at $0.75 at the most recent close of the market. An investor can expect a potential return of 833.33% based on the average XLO price forecast.
Analyzing the XLO fundamentals
Gross Profit Margin for this corporation currently stands at 0.86% with Operating Profit Margin at -9.4%, Pretax Profit Margin comes in at -9.18%, and Net Profit Margin reading is -9.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.82, Equity is -2.38 and Total Capital is -1.36. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.46.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7121 points at the first support level, and at 0.6725 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7881, and for the 2nd resistance point, it is at 0.8245.
Ratios To Look Out For
It is important to note that Xilio Therapeutics Inc [NASDAQ:XLO] has a current ratio of 2.21. On the other hand, the Quick Ratio is 2.21, and the Cash Ratio is 2.03. Considering the valuation of this stock, the price to sales ratio is 6.14, the price to book ratio is 1.95.
Transactions by insiders
Recent insider trading involved Frankenfield Christopher James, Chief Financial Officer, that happened on Jan 02 ’25 when 6954.0 shares were sold. SVP, FINANCE AND ACCOUNTING, Brennan Kevin M. completed a deal on Jan 02 ’25 to sell 1803.0 shares. Meanwhile, 10% Owner GILEAD SCIENCES, INC. bought 1.76 million shares on Dec 18 ’24.
